You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
东阳光药(01558.HK):递交甘精胰岛素注射液境内生产注册获受理
格隆汇 10-16 18:01

格隆汇 10 月 16日丨东阳光药(01558.HK)宣布,公司已经获得国家药品监督管理局关于甘精胰岛素注射液境内生产注册的受理通知书,该产品受理号为CXSS2000052国,是公司自主研究及开发的产品。

甘精胰岛素是一种长效人胰岛素类似物,用于治疗I型和II型糖尿病,能够更长效、平稳地控制患者的血糖。根据国际糖尿病联盟2019年报告数据,中国大陆糖尿病患者数量约为1.16亿,20–79岁人群中发病率约为10.4%。根据艾美仕数据,2019年中国糖尿病领域药物销售金额约为39.21亿美元,较2018年增长率约为8.97%,其中2019年国内胰岛素及其类似物类药物销售金额的份额约为42.52%,具有可观的市场潜力。

公司在糖尿病治疗领域拥有全面规划,布局了完整的产品线。公司产品重组人胰岛素注射液已于日前获批,目前已展开对该品种的市场推广工作。未来该产品如顺利通过上市审评审批,将进一步丰富公司糖尿病治疗领域的产品组合。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account